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Development of anergy to delayed-type hypersensitivity
antigens following renal allotranspiantation
R.D. GUTTMANN, J.L. MEAKINS, D.D. MOREHOUSE, and C. MILNE
Transplantation Service, Royal Victoria Hospital and McGill University, Montreal, Quebec, Canada
Development of anergy to delayed-type hypersensitivity antigens follow-
ing renal allotransplantation. A study is reported of patients receiving
180 renal allotranspiants and at risk for 1 or more years who had
pretranspiant and posttransplant skin tests using delayed type hyper-
sensitivity (DTH) recall antigens. Pretranspiant skin testing revealed an
incidence of 14% anergic patients prior to a first transplant, and 35%
were anergic prior to a second allograft. There was a statistically
significant correlation between pretranspiant anergy and age, as well as
a significant correlation between pretransplant anergy and time of
dialysis-dependent uremia. The conversion to the anergic state post-
transplant in those patients with surviving allografts increased annually
for the first 5 years as a linear function, with 69% of the population at
risk with their first transplant exhibiting anergy by 5 years. In those
patients receiving second renal transplants, all were anergic by 4 years
posttransplant. In vitro tests of lymphocyte function using mitogen
stimulation did not reveal significant differences between anergic and
responsive patients. In this series of 180 allografts there were 14 late
deaths. Eleven of these were in anergic patients and in 10 instances
were related to sepsis or malignancy. Three patients who were skin-test
responsive at the time of death died from cardiovascular causes. It is
concluded that there is an increasing risk of the development of anergy
to DTH antigens posttransplant and that the type of late mortality may
be marked by this hyporeactive state.
Développement de l'anergie aux antigènes d'hypersensibilite retardée
après allotransplantation rénale. Cette étude est un rapport concernant
des malades qui ont recu 180 allotransplants, qui ont été exposés
pendant un an ou plus et qui ont eu des tests cutanés avant et apres
transplantation avec des antigènes d'hypersensibilité retardée. Avant
une premiere transplantation 14% des malades étaient anergiques et
35% aprCs une seconde transplantation. II y avait une correlation
statistiquement significative entre l'anergie avant transplantation et
l'age et une correlation statistiquement significative entre l'anergie
avant Ia transplantation et Ia durée d'urémie ndcessitant Ia dialyse. Le
passage a l'état anergique post-transplantation chez les malades dont
les transplants étaient fonctionnels a augmente annuellement pendant
les cinq premiCres années comme une fonction lindaire, 69% de la
population exposée transplantee pour la premiere fois étant anergique
aprés 5 ans. Les malades transplantes pour Ia seconde fois Ctaient tous
anergiques 4 ans après une transplantation. Les tests in vitro de
fonction lymphocytaire utilisant la stimulation mitogCne n'ont pas
rCvélé de differences significatives entre les malades anergiques et les
autres. Dans cette série de 180 transplantations il y a eu 14 morts
tardives. Onze d'entre elles concernaient des malades anergiques et
étaient liées dans 10 cas a des septicémies ou des néoplasies. Trois
malades non anergiques sont morts d'affections cardio-vasculaires. II
est conclu qu'il y a un risque croissant de ddveloppement d'une anergie
aux antigenes DTH après Ia transplantation et que Ia cause de Ia
mortalité tardive peut étre affectde par cet état hyporeactif.
immune responsiveness. It is well known that two of the major
nonspecific causes of impaired responsiveness to DTH antigens
are the development of uremia [1—5] and immunosuppressive
drug therapy in a variety of diseases [5, 6]. The renal transplan-
tation patient population is at risk to develop anergy induced by
both of these known causes. Previous studies have documented
that the anergic state to recall antigens may exist in as many as
60% of a population of end-stage renal disease patients prior to
transplantation [7]. It was the objective of this study to attempt
to define the incidence and sequential development of anergy to
DTH recall antigens in a population of patients receiving renal
allotranspiants by identification of DTH status prior to tran-
plantation and by serial testing on annual basis. The results of
these observations carried out in recipients of 180 renal trans-
plants at risk 1 to 8 years are presented.
Patient population. From the period January 1, 1971, to
October 15, 1978, 180 renal transplants were carried out at this
institution. There were 49 living related donor transplants and
131 nonliving donor transplants. In the living related group, 45
were first transplants, 3 were second transplants, and I was a
third transplant. In the nonliving donor group, there were 106
first transplants, 23 second transplants, and 2 third transplants.
All patients who were in end-stage renal failure and referred to
the Transplantation Service for evaluation of their candidacy
for transplant and subsequently received transplants were in-
cluded in this study. Followup was obtained at annual intervals
in those patients whose graft survived 1 year or longer and for
as long as the graft was surviving. Followup skin testing was not
available when patients underwent graft failure, died, or in a
few instances where patients were cared for in another region
and did not return to the center for annual evaluation. There-
fore, the study examines the development of anergy in those
patients who are surviving with functioning renal allografts at
least 1 year or longer.
Prior to renal transplantation, at the time of medical evalua-
tion with informed consent, DTH skin testing was carried out
The response to delayed-type hypersensitivity (DTH) anti-
gens or skin-sensitizing chemicals with subsequent recall
evoked by skin testing is considered to be a measure of cellular
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dialysis patients, and normal controls. Mononuclear cells were
separated by a Ficoll-hypaque gradient [10], washed, and
counted. Triplicate microcultures were set up in Hepes buffered
RPMI 1640 medium containing 15% inactivated AB serum, at a
concentration of 1 x 106/ml [11]. Various mitogens obtained
from commercial sources were used as stimulants. Phytohem-
agglutinin-M (PHA, Difco) was added at a concentration of 10,
5, and 2.5 j.g of protein per 0.025 ml in a 0.2-ml culture, sealed
with microfilm, and harvested on day 3. Pokeweed mitogen
(Grand Island Biological Co.) was added in a serial dilution of
4x; 8X; and 16x per 0.025 ml into 0.2-mi cultures, sealed, and
harvested on days 3 and 6. Concanavalin A (12.5 pg, 5 .g, and
2.5 p.g per 0.025 ml; Sigma Chemical Co.) was added to
cultures, sealed, and harvested on day 6. On the appropriate
day, cultures were pulsed with 5 Ci of 1251odo-2 deoxyuridine
for 4 hours, harvested on a MASH II [12], and counted for
radioactivity.
Each cell preparation was simultaneously tested for rosette-
forming T-lymphocytes. Total T-lymphocyte cultures were set
up with sheep RBC and left overnight at room temperature. On
the following morning, the percent of lymphocytes forming
rosettes were counted [13]. The absolute number of T-lympho-
cytes was computed on the basis of a total white cell count done
on a Coulter counter the same day.
Results
The development of anergy in patients receiving their first
living or nonliving donor transplants is seen to be linear over the
course of the first 5 years posttransplant (Fig. 1). In this group
of patients receiving first transplants, 14% were found to be
anergic prior to transplantation, and the percentages of patients
with surviving grafts that demonstrated anergy at annual inter-
vals were 27% at 1 year, 36% at 2 years, 58% at 4 years, 69% at
5 years, 68% at 6 years, 75% at 7 years, and 89% at 8 years. The
living donor first-transplant group had an pretransplant inci-
dence of anergy of 16%, which reached 65% by 5 years,
compared to a pretransplant incidence of 13% and a 5 years'
incidence of 71% in the nonliving donor first-transplant group.
There were no important differences observed in these groups
on a year-by-year analysis. Patients who received second renal
transplants (Fig. 2) had a higher initial pretransplant anergy
fraction of 35%, and by 4 years posttransplant all patients with
functioning allografts were anergic. The increasing number of
annual conversions of patients to the anergic state is due to
conversions rather than due to graft loss, death, or lack of
followup in the group of responsive patients. Figure 3 shows the
number of conversions to the anergic state on a year-by-year
basis for recipients of first allografts. It can be seen that the
living donor recipient population converts to anergy somewhat
later than the nonliving donor recipients do.
Table 1 demonstrates the relationship between age at the time
of transplant and the presence of anergy in patients receiving
their first transplants. The older patient was more likely to be
anergic at the time of transplant than a younger patient was.
The mean age of the anergic group pretransplant was 43 years,
and the responsive group was 34 years. With Student's t test,
the data was statistically significantly different with P < 0.005.
Table 2 indicates the relationship between the duration of
dialysis prior to transplantation and the presence of pretrans-
plant anergy in those patients receiving their first renal trans-
plant. The anergic patients had been dialysis-dependent an
100
>80(0
60
0) 40
(0
0
(0
C(00
C,C
20
2 3 4 5 6
0
Time, years
Fig. 1. Incidence of anergy and allograft survival in serially studied
patients as afunction of time. There is a linear increase of anergy (solid
line) over at least a 5-year period of observation in patients with first
transplants, either from living or nonliving donors, beginning with a
14% frequency pretransplant and 69% by 5 years. From the survival
curve (broken line), it can be seen that allograft failure long term does
not decrease at the same rate as the anergy incidence is increasing.
by 0. l-ml intradermal inoculation of seven skin-test antigens on
the inner aspect of the forearms. These were coccidiodin (1: 100;
Cutter), histoplasmin (1:100; Parke-Davis), trichophytin (1000
protein nitrogen units (PNU)/ml; Hollister-Stier), mumps (undi-
luted, Eli Lilly), candida (1:100; Hollister-Stier), varidase (100
PNU/ml; Lederle), and intermediate strength PPD (5 TU;
Connaught). The skin reactions were placed and read by an
experienced allergy clinic nurse for induration and erythema at
24, 48, and 72 hours. Patients were considered anergic if there
was a lack of response as defined by less than a 5-mm
induration to all antigens or less than a 10-mm erythema only to
a single antigen [8], with the exception of mumps where more
than 15 mm of erythema or induration was considered positive.
These tests were repeated posttransplant when patients were
admitted for annual medical evaluations during the time period
of this study. Unpublished observations at our institution
demonstrate that repeated skin testing in a control population
does not alter subsequent responses; thus the annual testing of
each patient was interpreted as a valid independent measure.
The data was collated and grouped according to whether the
cases represented a living or nonliving donor transplant and
whether it was a first or second renal transplant. Because only 3
third transplants were performed, these have been excluded
from analysis. Five patients who received 2 renal transplants
during the study period are recorded twice, each as recipients of
first and second transplants. The pretranspiant anergy status
recorded in second transplant cases was that measured prior to
the second transplant.
Other potentially related variables evaluated with respect to
the anergy patients status included age, time on dialysis, and
where mortality occurred during the course of survival with a
functioning allograft, the primary cause of mortality.
Numerical data was processed by programs of the McGill
University Computing Centre, and statistical analysis was done
with the Student's t test and x2 square program. Allograft
survival was calculated by an actuarial method [9].
In vitro studies. Fresh heparinized blood (30 ml) was drawn
from a group of randomly selected long-term transplant, uremic
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2 3 4 5 6 7 8 Fig. 3. Time interval at which post-transplant conversion from respon-
sive to the anergic state took place in the nonliving donor and living
me, years donor recipients of first transplants only. It can be seen that a
significant percent of the conversions were occurring in both patient
groups each year after transplantation, and by 5 to 6 years the group
receiving nonliving donor grafts were anergic whereas by 7 to 8 years
the living donor recipient group had lost responsiveness.
Table 1. Relationship between age and DTH in recipients of first transplants
Living donors Nonliving donors Total
N Age, yr N Age, yr N Age, yr
Anergicb 7 39 14 44 21 43
Responsive' 38 29 92 37 130 34
By Student's two-tailed t test, the values were significant at P < 0.005.
b Forty-three percent were more than 50 years old.
Eleven percent were more than 50 years old.
Table 2. Relationship between time of dialysis-dependent uremia and delayed-type hypersensitivity antigens (DTH) in recipients of first
transplants'
Living donors Nonliving donors Total
Dialysis time Dialysis time Dialysis time
N months N months N months
Anergicb 7 29 14 20 21 23
Responsive' 38 6 92 13 130 9
a By Student's two-tailed t test, values were significant at P < 0.002.
b Sixty-one percent were on dialysis more than 2 years.
Nine percent were on dialysis more than 2 years.
average of 23 months prior to transplantation, whereas respon-
sive patients had been on dialysis for an average of 9 months.
With Student's t test, the data was statistically significantly
different, with P < 0.002. Of the anergic patients, 61% had been
on dialysis more than 2 years, but only 9% of the responsive
population had been on dialysis for 2 years or more.
There was no apparent relationship between the dose of
immunosuppressive medication during the first post-transplant
year and the development of anergy. All patients 1 year or more
posttransplant are on a standard regimen of chemical immuno-
suppression, which varies between 75 and 125 mg daily of
azathioprine and 10 and 15 mg daily of prednisone. Twenty-six
patients were taking 20 to 30 mg of prednisone on alternate
days. The amount of immunosuppression that is given in the
first posttransplant year amounts to 17 to 20 g of corticosteroid
and 27 to 45 g of azathioprine. Some patients had an additional 2
to 4 g cyclophosphamide during the first 6 months as part of
immunosuppressive drug infusions to treat rejection, and anti-
lymphocyte globulin is not routinely used.
Twenty-six patients were placed on alternate-day prednisone
(20 to 30 mg every other day) and received daily azathioprine.
Of those on alternate-day prednisone during the first post-
transplant year, 4 of 13 patients showed no change in subse-
quent anergy status, and 9 developed anergy. Of those 13
converted to alternate-day prednisone during years I to 3, 8
showed no change in status, and S subsequently developed
anergy.
In the entire population of patients receiving first transplants,
4 of the 15 patients who were anergic pretranspiant and whose
gi-afts functioned at 1 year or later converted to the responsive
state posttransplant. These patients have been at risk for 1, 2, 7,
and 8 years, respectively. The latter 2 patients reconverted to
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Fig. 2. Incidence of anergy in patients who received second renal
transplants. Thirty-five percent of the patients entered the program
anergic, had varying periods of hemodialysis and immunosuppression
with their first allograft, and all were anergic by 4 years after receiving
their transplant.
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the anergic state at years 4 and 5. None of the patients receiving
second transplants who were anergic pretranspiant converted
to a responsive state posttransplant.
There were 14 patients with graft function for 2 or more years
who died during the observation period of this study (Table 3).
Five patients had received a second renal transplant, and 4 of
these were anergic prior to death. Nine of the deaths occurred
in patients with a first renal transplant, and 7 were anergic prior
to death. It is of interest that of the 11 patients who were
anergic, 10 died primarily of infectious causes or malignancies.
Ir 4 of 6 of these patients, the infectious cause was gram-
negative bacterial sepsis associated with long-standing chronic
aggressive hepatitis and the HBs antigen carrier state. Four
patients died with metastatic malignancies of a variety of
histologic types. In the 3 responsive patients, death was related
to cardiovascular causes, with myocardial infarction in 2 cases
and a cerebrovascular accident in the 3rd. Analysis of these
data by x2 reveal a statistically significant difference, with P <
0.02 and Fischers exact probability = 0.01.
In vitro testing of patients' peripheral blood lymphocytes at
various times posttransplant for mitogen responsiveness and T
lymphocyte enumeration did not reveal striking differences
between the uremic and posttransplant population as a whole
when compared to normal controls. The uremic and posttrans-
plant population show slightly decreased PHA and ConA
responses compared with normal. The absolute number of
circulating total T lymphocytes was also slightly less than it was
in normal controls. Similarly, there was not a striking difference
between the anergic and responsive patients (Table 4). Al-
though there was a slight reduction of circulating total T
lymphocytes in the anergic population compared with the
responsive population, mitogen responsiveness was not mark-
edly different.
Discussion
The incidence of pretransplant anergy in the uremic popula-
tion receiving transplants at this institution was 14%, which
Table 3. Causes of late outcome of death in patients according to
status of delayed-type hypersensitivity antigensa
Septic or
cancer Cardiovascular
Anergic 10 1
Responsive 0 3
a Onehundred eighty cases at risk >1 year since 1971, which includes
9/151 first, 5/26 second, and 0/3 third allografts. x2 = 5.61, P < 0.02;
Fisher's exact probability = 0.01.
contrasts with the report by Rolley et al, whose population
consisted of 60% (20/33) anergic patients [7]. In their popula-
tion, the mortality rate was increased in patients who had
pretransplant anergy whereas graft loss from rejection was
somewhat reduced in this population compared with the re-
sponsive population. Because the numbers were small, they did
not achieve statistical significance. In terms of outcome, they
further analyzed a larger population of patients who underwent
DNCB sensitization and measured the ability to sensitize and
recall a reaction to this chemical antigen. Their data suggested
that the DNCB unresponsive patient was likely to incur mortal-
ity but also had a better chance for graft survival than the
DNCB responsive patient had [7]. These results have been
confirmed by Watson et al, who found a 71% 6-month graft
survival in weak DNCB responders compared with a 15%
survival in strong responders [141. No attempt was made to
carry out deliberate chemical sensitization in our population,
but the numbers of anergic patients pretransplant in our series
was small and our data does not suggest a correlation with
either allograft survival or mortality. The reason for this differ-
ence may be that the mortality rate in our series is less than 10%
in the first posttransplant year and less than 3% per year at risk
over the period of study. The difference in incidence of pre-
transplant anergy in transplant programs may reflect the differ-
ences in patient populations at risk and treated with respect to
nutrition, uremia, age, and other variables. Furthermore, these
differences may be relevant to complication rates reported.
Such significant correlations between mortality, infection rate,
and outcome with DTH responses have been made in patients
undergoing major surgery [15, 16].
In the analysis of the possible variables related to the anergic
state, it was found that both the length of time on dialysis prior
to a first transplant and the age of the patient were factors that
may influence who enters a posttransplant period already
anergic. This would lend confirmation to the report of a
correlation between the length of dialysis-dependent uremia
and the response to a single DTH antigen [2]. Because the
mechanisms involved in the anergic state pretransplant and
presumably related to uremia may be quite different from the
mechanism posttransplant, further characterization of the pre-
transplant and posttransplant populations may be informative.
The data presented here indicate that there is a progressive
linear increase in the incidence of anergy to recall skin test
antigens as a consequence of long-term survival with a renal
allograft and treatment with immunosuppressive drugs. Immu-
nosuppressive drug therapy is relatively constant from 1 year
posttransplant on, and this observation in the total population is
not accounted for by the loss of allografts or deaths of respon-
sive patients. The reasons for this continued conversion may be
Table 4. In vitro mitogen responsiveness in 51 long-term patients according to status of delayed-type hypersensitivity antigensa
Phytohemagglutinin, cpm
Day 3
Pokeweed mitogen, cpm .Concanavalin A, cpm
Day 3
T-Lymphocytes
%
T-Lymphocytes
counts/mm3 whole bloodDay 3 Day 6
Anergic(N = 32)
Responsive(N = 21)
14,471 1803
11,619 2384
6063 607
5952 905
7118 949
10,004 1789
4925 452
5966 1215
61 2
64 3
650 066
840 096
Values are the means 5EM.
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related to the continued immunosuppression, persistance of
latent viral infections, as well as chronic allograft stimulation.
The use of alternate day steroids was not associated with
reversals of the anergic to the responsive state, but these
patients are still maintained on an immunosuppressive regimen
with daily azothioprine. This association of anergy with immu-
nosuppressive medications was not totally attributable to corti-
costeroids as has been observed in a cross-sectional study of
DTH responses in hospitalized patients [17]. In a study of DTH
reactions in autoimmune diseases, depression of these respons-
es were related more to combined azathioprine-corticosteroid
therapy than they were to one steroid alone [18].
Although in vitro immunologic testing suggests that the
posttransplant population as well as the pretransplant popula-
tion shows somewhat reduced levels of circulating T lympho-
cytes, the degree of responsiveness to mitogen stimulation was
not extraordinarily low. No attempt was made to document
lymphocyte responses to the specific skin-test antigens in in
vitro culture. These findings are in support of in vitro data
obtained in studies of patients treated with immunosuppressive
drugs [5, 6]. It is further emphasized that this suggests that
mitogen responsiveness that is related to the function of lym-
phocytes and macrophages in vitro is relatively intact despite
the absence of DTH reactions to recall antigens in vivo.
Furthermore, these types of in vitro tests do not appear to be an
important criterion for selectively marking subpopulations of
patients because they were not significantly different when the
data was analyzed in terms of the anergic or the responsive
population. Similar observations have been made in a surgical
population of patients studied by in vitro lymphocyte function
techniques and DTH reactivity [19]. Thus, the in vivo observa-
tions appear to more accurately reflect the marking of two
distinct patient subpopulations at a given point in time whose
outcome may be different long term.
The course of most patients from 1 to 8 years posttransplant
was generally quite benign, usually associated with good renal
function, and with no undue incidence of late infectious compli-
cations. But, several late deaths occurred, and of a total of 11
patients who died that were anergic posttransplant, 4 deaths
were a consequence of metastatic carcinoma, and 6 patients
died of sepsis. In the 3 patients who died posttransplant but
were DTH-antigen responsive, the primary cause was cardio-
vascular. Only one death was due to cardiovascular causes in
the anergic patient group. This would suggest that the presence
of the anergic state may be associated with and should alert one
to the mode of long-term mortality.
The role of anergy and its relationship to malignancy is well
characterized [20]. It is not clear whether or not the anergic
state is a consequence of the development of widespread tumor
or whether or not the anergic state may be a predisposing factor
to the development or spread of tumor. Because, in the serial
observations recorded here, the anergic state clearly preceded
the development of malignancy by 2 to 5 years in the 4 patients,
it thus could be considered as a possible significant risk factor
although the relatively few cases leading to death makes this
association weak at the moment. Whether the abolition of the
DTH-responsive state and an increased susceptibility to cancer
in these patients can be related to removing a mechanism of
immune surveillance, antiviral immunity, or to a direct mitogen-
ic effect of immunosuppressive chemicals is speculative. It is of
interest that the progression of the metastatic malignancy from
the time of diagnosis to death was extremely rapid. In terms of
those patients who died a septic death and were anergic, it is
clear that in our population, carriers of HBs antigen with
evidence of chronic aggressive hepatitis may either be anergic
or responsive on skin testing at any period of time; but most
eventually develop complete anergy and may be at more risk to
subsequently develop long-term sepsis in association with liver
dysfunction.
Anergy develops in patients who received nonliving or living
donor allografts and in patients who had good as well as poor
tissue matches, including patients who received HLA identical
grafts and no extra immunosuppression for rejection crises, of
whom 4/6 have already converted to the anergic state. Thus, it
is speculated that the long-term development of anergy is
multifactorial, related to preexisting host and treatment varia-
bles, long-term immunosuppression, acquired viral illnesses,
and chronic allograft stimulation. Multiple cellular and humoral
mechanisms may be operative in the lack of expression of DTH
in this complex patient population.
Reprint requests to Dr. R. D. Guttmann, Transplantation Service,
Royal Victoria Hospital, 687 Pine Ave. W., Montreal, Quebec, Canada
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